ObsEva Announces First Quarter 2021 Financial Results and Business Update

ObsEva Announces First Quarter 2021 Financial Results and Business Update




ObsEva Announces First Quarter 2021 Financial Results and Business Update

 

Yselty® for uterine fibroids: US New Drug Application submission planned in Q3:21; European marketing approval recommendation anticipated in Q4:21

Yselty® for endometriosis: Readout from Phase 3 EDELWEISS 3 study expected in Q4:21

Ebopiprant: Phase 2b dose ranging study planned to initiate in Q4:21 based on positive Phase 2a proof of concept

Actively pursuing new indications and partnerships to maximize value of pipeline candidates

                

GENEVA, Switzerland and BOSTON, MA May 6, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN) (ObsEva or the Company), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today reported financial results for the quarter ended March 31, 2021 and provided a business update.

“The outset of 2021 was marked with a prioritization of capitalization and commercialization, and we have made significant progress on both fronts,” said Brian O’Callaghan, CEO of ObsEva. “In the first quarter of 2021, we raised over $60 million in gross equity proceeds, providing the capital needed to continue to advance our pipeline, reach multiple clinical and regulatory milestones, and execute on our well-defined strategic plan. On the commercialization front, we have created significant optionality and momentum with numerous negotiations that have reached an advanced stage. We plan to build on this momentum and select the best potential partners and strategies for each of our programs and look forward to providing additional updates in due course.”

 

Anticipated Milestones

ObsEva aims to achieve the following key clinical and regulatory objectives in 2021:

  • Yselty for uterine fibroids: NDA submission (Q3:21); MAA approval recommendation (Q4:21)
  • Yselty for endometriosis: Phase 3 EDELWEISS 3 primary endpoint readout (Q4:21)
  • Ebopiprant for treatment of preterm labor: Phase 2b dose ranging study initiation in EU/Asia (Q4:21)

 

Pipeline Update

Yselty for the treatment of uterine fibroids and endometriosis

  • Yselty for Uterine Fibroids:   ObsEva is developing Yselty, an oral GnRH receptor antagonist with the potential to treat more women due to its potential best-in-class efficacy, a favorable tolerability profile and unique, flexible dosing options for the treatment of uterine fibroids. Following the European Medicine Agency’s (EMA) validation of the marketing authorization application (MAA), a major milestone toward making Yselty available in the EU, the Company continues to work closely with the EMA to achieve marketing approval, with an approval recommendation from the Committee for Medicinal Products for Human Use (CHMP) projected in Q4:2021 and formal product approval expected to follow shortly thereafter. The Company is also working to submit a U.S. New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA), projected in Q3:2021, that will include the Week 76 post-treatment follow-up results from the Phase 3 PRIMROSE 1 (US only; n=574) and PRIMROSE 2 (Europe and US; n=535) clinical studies. In addition, the Company recently announced commencement of an observational study (PRIMROSE 3) of bone mineral density in women who completed at least 20 weeks of treatment in either of the PRIMROSE 1 or 2 studies.
  • Yselty for Endometriosis: The EDELWEISS 3 study in the EU is progressing as planned, with randomization of patients recently completed and primary endpoint data expected in Q4:2021. The ongoing Phase 3 EDELWEISS 3 study (Europe and US) is designed to enroll approximately 450 patients with endometriosis-associated pain, with a co-primary endpoint of response on both dysmenorrhea (menstrual pain) and non-menstrual pelvic pain. The study includes a 75 mg once-daily dose without hormonal ABT (1 mg estradiol / 0.5mg norethindrone acetate), and a 200 mg once-daily dose in combination with hormonal ABT. Subjects who have completed the initial six-month treatment period will have the option to enter a six-month treatment extension.

Ebopiprant for Treatment of Preterm Labor:   Preparations are ongoing to initiate a Phase 2b clinical study in Q4:21. The Phase 2b dose ranging study will build on the recently announced PROLONG Phase 2a proof-of-concept study, which demonstrated early clinical efficacy and safety in pregnant women with spontaneous preterm labor. Given ebopiprant is currently the only known product in development for this indication and based on its innovative mechanism of action and positive topline data, the Company plans to discuss with European regulators a possible accelerated registration program based on a Phase 2b/3 adaptive design.    In parallel with development of ebopiprant in Europe and Asia, the Company is also actively evaluating the regulatory strategy for ebopiprant development in the United States, where there are currently no FDA-approved tocolytic medications available for treatment of preterm labor.

Nolasiban for In Vitro Fertilization:   ObsEva is also advancing nolasiban, an oral oxytocin receptor antagonist, to improve live birth rates in women undergoing in vitro fertilization.

 

Financial Update

Net loss for the quarter ending March 31, 2021 was $20.0 million, or $0.29 per share, compared with a net loss of $21.9 million, or $0.48 per share, for the quarter ending March 31, 2020. Research and development expenses were $15.5 million and general and administrative expenses were $4.2 million for the quarter ended March 31, 2021, compared with $17.2 million and $3.7 million, respectively, for the prior year quarter. The net loss for the quarter ended March 31, 2021 included non-cash expenses of $2.0 million for stock-based compensation, compared with $2.7 million for the prior year period.

As of March 31, 2021, ObsEva had cash and cash equivalents of $68.0 million, compared with $31.2 million as of December 31, 2020. On March 5, 2021, ObsEva entered into a Sale Agreement with SVB Leerink LLC (SVB Leerink) to offer and sell common shares having an aggregate offering price of up to $50 million from time to time through an at the market offering under which SVB Leerink will act as sales agent.

The first quarter 2021 financial report will be available in the financial reports section of the Company’s website.

To access the financial reports section of the Company’s website, please click [here].

To access the first quarter 2021 financial report directly, please click [here].

 

About ObsEva

ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.

 

Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and other similar expressions, and are based on ObsEva’s current beliefs and expectations. These forward-looking statements include expectations regarding the potential therapeutic benefits and the clinical development of ObsEva’s product candidates, the potential for new indications for any of ObsEva’s product candidates, the timing of enrollment in and data from clinical trials, expectations regarding regulatory and development milestones, including the potential timing of regulatory submissions to the EMA and FDA, the timing of and ObsEva’s ability to obtain and maintain regulatory approvals for its product candidates, the results of interactions with regulatory authorities and the potential to raise additional funds or enter into strategic partnerships in the future. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials and clinical development, including the risk that the results of earlier clinical trials may not be predictive of the results of later stage clinical trials, related interactions with regulators, ObsEva’s reliance on third parties over which it may not always have full control, the impact of the novel coronavirus outbreak, and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for the year ended December 31, 2020 and other filings ObsEva makes with the U.S. Securities and Exchange Commission. These documents are available on the Investors page of ObsEva’s website at http://www.ObsEva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

 

For further information, please contact:

CEO Office Contact:
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550

Investor Contact:
Joyce Allaire
jallaire@lifesciadvisors.com
+1 (617) 435-6602

 

 

                 Exhibit 99.3

Consolidated Statements of Comprehensive Loss

    Three-month period
ended March 31,
 
(in USD ’000, except share and per share data) – unaudited   2021     2020  
Operating income other than revenue     6       4  
OPERATING EXPENSES                
Research and development expenses     (15,516 )     (17,188 )
General and administrative expenses     (4,191 )     (3,709 )
Total operating expenses     (19,707 )     (20,897 )
OPERATING LOSS     (19,701 )     (20,893 )
Finance income     629       60  
Finance expense     (911 )     (1,011 )
NET LOSS BEFORE TAX     (19,983 )     (21,844 )
Income tax expense     (21 )     (19 )
NET LOSS FOR THE PERIOD     (20,004 )     (21,863 )
Net loss per share                
Basic     (0.29 )     (0.48 )
Diluted     (0.29 )     (0.48 )
Weighted Average Number of Shares Outstanding     68,574,364       45,725,561  

 

 

Consolidated Balance Sheets

(in USD ’000) – unaudited   March 31,
2021
    December 31,
2020
 
ASSETS                
Current assets                
Cash and cash equivalents     67,998       31,183  
Other receivables     364       397  
Prepaid expenses     4,607       5,388  
Total current assets     72,969       36,968  
Non-current assets                
Right-of-use assets     1,271       1,425  
Furniture, fixtures and equipment     133       151  
Intangible assets     26,608       26,608  
Other long-term assets     280       295  
Total non-current assets     28,292       28,479  
Total assets     101,261       65,447  
LIABILITIES AND SHAREHOLDERS’ EQUITY                
Current liabilities                
Other payables and current liabilities     5,708       10,760  
Accrued expenses     10,622       10,248  
Current lease liabilities     674       696  
Total current liabilities     17,004       21,704  
Non-current liabilities                
Non-current lease liabilities     731       952  
Non-current borrowings     25,411       25,300  
Post-employment obligations     7,790       8,218  
Other long-term liabilities     858       919  
Total non-current liabilities     34,790       35,389  
Shareholders’ equity                
Share capital     6,948       4,878  
Treasury shares     (938 )     (304 )
Share premium     414,483       356,822  
Reserves     28,373       26,353  
Accumulated losses     (399,399 )     (379,395 )
Total shareholders’ equity     49,467       8,354  
Total liabilities and shareholders’ equity     101,261       65,447  

###

 

 

Attachment